Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..
November 05, 2023
Share
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC made a proposal to acquire remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE) for $25 million on October 25, 2023. Newtyn proposed to acquire remaining shares of Sensei Biotherapeutics, Inc. at a price equal to $1.00 per share in cash. Proposal is subject to receipt of required Board and stockholder approvals; receipt of any required governmental and third-party approvals (including under applicable antitrust laws and material contracts); satisfactory completion of due diligence; and the execution of a definitive agreement containing terms and conditions customary for a transaction of this type and size. The transaction would not be subject to any financing contingency.
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE) on November 6, 2023. Sensei's Board of Directors reviewed Newtyn?s proposal and determined unanimously that the proposal substantially undervalues the Company and its future prospects and is not in the best interests of the Company and its stockholders. Accordingly, on November 6, 2023, the Board rejected Newtyn?s proposal.
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..
SENSEI BIOTHERAPEUTICS, INC. 
